Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | RHEB | Q15382 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21839944 | 0.83 | MAPK10 (0.36) | MAPK10KDM4EUSP2SMN1; SMN2NOTUM | |
| SCHEMBL30444724 | 0.83 | MAPK10 (0.36) | MAPK10KDM4EUSP2SMN1; SMN2NOTUM | |
| SCHEMBL12709757 | 0.81 | KDM4E (0.53) | DUTKDM4ESMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL21624151 | 0.80 | DUT (0.40) | DUT | |
| SCHEMBL29968395 | 0.80 | DUT (0.40) | DUT | |
| SCHEMBL16899416 | 0.78 | NOTUM (0.43) | MAPK10KDM4EUSP2SMN1; SMN2NOTUM | |
| SCHEMBL21839919 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL30444026 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL31300570 | 0.76 | NPC1 (0.38) | MAPK10KDM4EUSP2SMN1; SMN2NOTUM | |
| SCHEMBL20605036 | 0.76 | NPC1 (0.38) | MAPK10KDM4EUSP2SMN1; SMN2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-08-08 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| EP-3612520-B1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMA (KR) | 2021-11-10 | — | — | EP | disclosed |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2021-06-24 | — | — | US | disclosed |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-27 | — | — | US | disclosed |
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2020-04-16 | — | — | US | disclosed |
| EP-3612520-A1 | AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF | Il Dong Pharmaceutical Co., Ltd. (KR) | 2020-02-26 | — | — | EP | disclosed |
| CN-110678450-A | Isoxazole derivatives as nuclear receptor agonists and uses thereof | 日东制药株式会社 | 2020-01-10 | — | — | CN | disclosed |
| WO-2018190643-A1 | AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | DUT 1896/4885MAPK10 4060/4885KDM4E 3805/4885 |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | DUT 2169/4885MAPK10 4021/4885KDM4E 3573/4885 |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | DUT 1896/4885MAPK10 4060/4885KDM4E 3805/4885 |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | DUT 2737/4885MAPK10 4257/4885KDM4E 4485/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | DUT 2169/4885MAPK10 4021/4885KDM4E 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.